HC Wainwright Increases Earnings Estimates for AC Immune

AC Immune (NASDAQ:ACIU) – Equities researchers at HC Wainwright upped their FY2027 EPS estimates for AC Immune in a research note issued on Monday, May 4th. HC Wainwright analyst A. Fein now forecasts that the company will earn $0.17 per share for the year, up from their previous estimate of $0.13. The consensus estimate for AC Immune’s current full-year earnings is ($0.69) per share. HC Wainwright also issued estimates for AC Immune’s FY2030 earnings at $1.65 EPS.

ACIU has been the subject of several other reports. Wall Street Zen upgraded AC Immune from a “sell” rating to a “hold” rating in a report on Saturday, February 28th. Weiss Ratings reiterated a “sell (d-)” rating on shares of AC Immune in a research note on Monday, April 20th. Jefferies Financial Group restated a “buy” rating and set a $7.00 price objective on shares of AC Immune in a research report on Friday, March 13th. Finally, BTIG Research restated a “buy” rating and issued a $8.00 target price on shares of AC Immune in a report on Monday. Two analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $7.50.

AC Immune Trading Up 2.3%

AC Immune stock opened at $3.05 on Tuesday. AC Immune has a 12 month low of $1.51 and a 12 month high of $4.00. The stock has a fifty day simple moving average of $2.93 and a two-hundred day simple moving average of $3.09. The firm has a market cap of $310.41 million, a price-to-earnings ratio of -3.72 and a beta of 1.66.

AC Immune (NASDAQ:ACIU) last announced its quarterly earnings data on Wednesday, April 29th. The company reported ($0.19) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.20) by $0.01. AC Immune had a negative net margin of 1,788.02% and a negative return on equity of 110.92%. The company had revenue of $1.40 million during the quarter, compared to analyst estimates of $0.33 million.

Institutional Trading of AC Immune

Large investors have recently added to or reduced their stakes in the business. EFG International AG purchased a new stake in shares of AC Immune in the 4th quarter worth $41,000. Marshall Wace LLP bought a new stake in AC Immune during the fourth quarter valued at about $586,000. Dimensional Fund Advisors LP increased its position in AC Immune by 20.5% in the fourth quarter. Dimensional Fund Advisors LP now owns 213,464 shares of the company’s stock worth $670,000 after buying an additional 36,353 shares in the last quarter. Acadian Asset Management LLC raised its stake in shares of AC Immune by 87.1% in the first quarter. Acadian Asset Management LLC now owns 371,177 shares of the company’s stock worth $679,000 after buying an additional 172,796 shares during the period. Finally, Susquehanna International Group LLP purchased a new position in shares of AC Immune during the 3rd quarter valued at about $63,000. 51.36% of the stock is currently owned by institutional investors.

About AC Immune

AC Immune AG is a clinical-stage biopharmaceutical company headquartered in Lausanne, Switzerland, with a subsidiary in Boston, Massachusetts. The company specializes in the discovery and development of therapeutics and diagnostics for neurodegenerative diseases, with a primary focus on Alzheimer’s disease, Parkinson’s disease and other protein misfolding disorders. AC Immune leverages proprietary platform technologies to identify and optimize candidates that target pathological protein aggregates.

Since its founding in 2003, AC Immune has advanced multiple programs into clinical development.